1. Scrip
  2. >>New Products

Teva/Celltrion's Truxima Is First Biosimilar Rituxan To Reach US Market

 
• By Jessica Merrill

Truxima will launch in the US on 11 November for oncology indications at a 10% discount to the list price of Roche’s innovator Rituxan. The launch marks Teva's first biosimilar launch in the US.

text 10 percentages discount 3d red white banner, letters and block, business concept
Truxima will launch at a 10% lower WAC than Rituxan • Source: Shutterstock

Teva Pharmaceutical Industries Ltd. and Celltrion Inc. will launch Truxima (rituximab-abbs), the first biosimilar version of Roche's blockbuster lymphoma drug Rituxan (rituximab) in the US, on 11 November. It marks the first US biosimilar launch for Teva, a generic powerhouse that nonetheless fell behind rivals in the race to bring the first wave of biosimilars to market.

The wholesale acquisition cost (WAC) for Truxima will be 10% lower than branded Rituxan, Teva said in announcing the launch...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.